Stay updated with breaking news from Agomab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- All dosing regimens were well-tolerated across the Phase 1 clinical study -- -- High local exposure to AGMB-129 in the ileum -- -- No clinically relevant systemic exposure to AGMB-129, confirming
-- Extension led by Pfizer with participation from new investors Walleye Capital and Asabys Partners as well as existing investors -- -- Funding will support next stage of clinical and corporate development
Agomab Therapeutics NV ('Agomab') today announced that Tim Knotnerus, Chief Executive Officer, will present a company overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference
Agomab Therapeutics NV ('Agomab') today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property.
-- Acquisition strengthens Agomab as a leader in targeting growth factor pathways -- -- Origo brings TGF-ß-targeted approach with clinical-stage program in Crohn's disease and preclinical candidate